HIV vaccine trial kicks off in South Africa

Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers. The regimen is based on one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand, which was the first study to demonstrate that a vaccine can guard against HIV infection. Results from the current trial--expected in two years--will help determine whether to take the vaccine regimen into a large-scale study. Report

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.